Rimadyl

Rimadyl Granules 8.75% w/w

Presentation

White, free-flowing granules containing carprofen 8.75% w/w.

Uses

Carprofen is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. In horses and ponies it is indicated for analgesic and anti-inflammatory action in musculo-skeletal disorders and after surgery.

Dosage and administration

The recommended dosage is 0.7 mg carprofen per kg bodyweight. In all cases it is recommended that this be provided initially by an intravenous injection of carprofen, followed by once daily oral administration of the granules for up to 4 or 9 days according to clinical response. One sachet of Rimadyl Granules treats 300 kg bodyweight. For animals below 150 kg the use of half a sachet is recommended.

Rimadyl Granules should be administered with a little feed, mixed in to ensure the full dose is eaten.

Contra-indications, warnings, etc

For oral administration only.

For specific information about the time which must elapse between treatment and competition, veterinary surgeons are advised to consult the authority responsible for the competition in question (e.g. the Jockey Club in the case of racing in the UK).

Do not exceed the stated dose or the duration of treatment.

Do not administer other NSAIDs concurrently or within 24 hours of each other.

Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects.

Do not use in animals suffering from cardiac, hepatic, renal disease where there is a possibility of gastro-intestinal ulceration or bleeding or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Use in any animal less than 6 weeks of age, or in aged animals, may involve additional risk. If such a use cannot be avoided animals may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. Concurrent administration of potential nephrotoxic drugs should be avoided.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

In the absence of any specific studies in pregnant target animals, such use is not indicated.

There is no specific antidote for carprofen overdosage but general supportive therapy as applied to clinical overdosage with NSAIDs should be applied.

For animal treatment only.

Withdrawal period

Not for use in horses intended for human consumption.

Treated horses may never be slaughtered for human consumption.

The horse must have been declared as not intended for human consumption under national horse passport legislation.

Operator warnings

Wash hands after use. Avoid inhalation of the product.

Pharmaceutical precautions

Do not store above 25°C. Protect from light. Store in a dry place.

Any unused, opened sachets should be discarded at the end of a course of treatment.

Any unused product or waste material should be disposed of in accordance with national requirements.

Keep out of reach of children.

Legal category

POM-V

Packaging Quantities

Cartons containing 20 sachets. Each sachet contains 2.4 g Rimadyl Granules (210 mg carprofen).

Further information

Both carprofen and warfarin may be bound to plasma proteins. Limited evidence indicates that binding is at different sites thus enabling concurrent use, but the clinical situation must be monitored carefully.

Marketing authorisation number

Vm 00057/4192.

GTIN (Global Trade Item No)

20 sachets:

05013457078381

Rimadyl Palatable Tablets 20 mg, 50 mg & 100 mg

Presentation

Rimadyl Palatable Tablets for dogs are square light brown tablets scored down the middle containing as active ingredient either 20 mg, 50 mg or 100 mg carprofen.

Uses

For analgesia and reduction of chronic inflammation, for example in degenerative joint disease of the dog. Rimadyl Palatable Tablets can also be used in the management of post-operative pain in dogs.

Dosage and administration

For oral administration. The tablets are palatable and are willingly consumed by most dogs when offered.

An initial dose of 2 to 4 mg carprofen/kg bodyweight/day is recommended to be given as a single dose or in two equally divided doses. Subject to clinical response the dose may be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single daily dose. To extend analgesic and anti-inflammatory cover post operatively, parenteral therapy with Rimadyl Small Animal Injection may be followed with Rimadyl Palatable Tablets at 4mg/kg/day for up to 5 days.

Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision.

Contra-indications, warnings, etc

The elimination time of NSAIDs, including carprofen, in the cat is longer than in the dog and the therapeutic index is narrower. In the absence of specific data the use of Rimadyl Palatable Tablets in the cat is contra-indicated.

Do not exceed the stated dose.

Do not administer other NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.

Use in dogs less than 6 weeks of age, or in aged dogs, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

Concurrent administration of potential nephrotoxic drugs should be avoided.

In the absence of any specific studies in pregnant bitches, such use is not indicated.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

For animal treatment only.

Due to the palatable nature of the tablets, store in a secure location. Severe adverse reaction may occur if large quantities are ingested. If you suspect your dog has consumed Rimadyl Palatable Tablets above the labelled dose, please contact your veterinarian.

There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.

In the event of accidental ingestion of the tablets, seek medical advice and show the doctor what has been taken.

Wash hands after handling the product.

Pharmaceutical precautions

Do not store above 25°C. Store in a dry place. Protect from light. Keep out of reach of children.

Any unused product or waste materials should be disposed of in accordance with national requirements.

Legal category

POM-V

Packaging Quantities

Containers of 14, 30 or 100 tablets x 20 mg, 14, 30 or 100 tablets x 50 mg, 14, 30 or 100 tablets x 100 mg

Further information

Experimental and clinical evidence suggests that for carprofen in the dog gastro-intestinal tract ulceration is rare, and only occurs at dosages well above the therapeutic dose.

Following repeated therapeutic dosing for 8 weeks, carprofen has been shown to have no detrimental effect on chronically arthritic canine cartilage in a model of canine osteoarthritis.

In addition, therapeutic concentrations of carprofen have been demonstrated (in vitro) to increase proteoglycan synthesis in chondrocytes from canine arthritic cartilage.

Stimulation of proteoglycan synthesis will narrow the difference between the rate of degeneration and regeneration of cartilage matrix resulting in a slowing of the progression of cartilage loss.

Marketing authorisation numbers

20 mg	Vm 00057/4215
50 mg	Vm 00057/4216
100 mg	Vm 00057/4217

GTIN (Global Trade Item No)

14 x 20 mg:

05013457079098

30 x 20 mg:

05013457079104

100 x 20 mg:

05013457079111

14 x 50 mg:

05013457079128

30 x 50 mg:

05013457079135

100 x 50 mg:

05013457079142

14 x 100 mg:

05013457079159

30 x 100 mg:

05013457079166

100 x 100 mg:

05013457079173

Rimadyl Tablets 20 mg & 50 mg

Presentation

Rimadyl Tablets are round white tablets scored down the middle containing as active ingredient either 20 mg or 50 mg carprofen.

Uses

For analgesia and reduction of chronic inflammation, for example in degenerative joint disease of the dog. Rimadyl tablets can also be used in the management of post-operative pain in dogs.

Dosage and administration

For oral administration.

An initial dose of 2 to 4 mg carprofen/kg bodyweight/day is recommended to be given as a single dose or in two equally divided doses. Subject to clinical response the dose may be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single daily dose. To extend analgesic and anti-inflammatory cover post operatively, parenteral therapy with Rimadyl Injection may be followed with Rimadyl tablets at 4 mg/kg/day for up to 5 days.

Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision.

Contra-indications, warnings, etc

The elimination time of NSAIDs, including carprofen, in the cat is longer than in the dog and the therapeutic index is narrower. In the absence of specific data the use of Rimadyl Tablets in the cat is contra-indicated.

Do not exceed the stated dose.

Do not administer other NSAIDs concurrently or within 24 hours of each other. Do not administer in conjunction with glucocorticoids.

Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.

Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

Concurrent administration of potential nephrotoxic drugs should be avoided.

In the absence of any specific studies in pregnant target bitches, such use is not indicated.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.

For animal treatment only.

In the event of accidental ingestion of the tablets, seek medical advice and show the doctor what has been taken.

Wash hands after handling the product.

Pharmaceutical precautions

Store in a dry place. Protect from light. Keep out of reach of children.

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

Legal category

POM-V

Packaging Quantities

Containers of 100 × 20 mg, 100 × 50 mg and 500 × 50 mg tablets.

Further information

Experimental and clinical evidence suggests that for carprofen in the dog gastro-intestinal tract ulceration is rare, and only occurs at dosages well above the therapeutic dose.

Marketing authorisation numbers

20 mg	Vm 00057/4190
50 mg	Vm 00057/4191

GTIN (Global Trade Item No)

100 x 20 mg:

05013457078350

100 x 50 mg:

05013457078367

500 x 50 mg:

05013457078374